Form 8-K/A Steele Creek Capital For: Aug 05
- U.S. Stocks Fall as Fears of Economic Slowdown Return
- Apple (AAPL) Extends Decline as BofA Downgrades to Neutral on More Balanced Risk/Reward
- Wall Street sell-off accelerates after brief respite
- CarMax (KMX) Drops 15% After a 'Horrendous' Earnings Report
- Bernstein's Top Indicator Triggers a Buy Signal, Suggests Short-term Tactical Bounce
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(Amendment No. 1)
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2022
Steele Creek Capital Corporation
(Exact name of registrant as specified in charter)
|(State or other jurisdiction of
incorporation or registration)
|(I.R.S. Employer |
|201 S. College Street, Suite 1690, Charlotte, NC||28244|
|(Address of principal executive offices)||(Zip Code)|
|(Registrant’s telephone number, including area code)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act: None
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
This Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”) is being filed by Steele Creek Capital Corporation (the “Company”) for the purpose of amending Item 3.02 Unregistered Sales of Equity Securities of that certain Current Report on Form 8-K originally filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on August 8, 2022 (the “Original Form 8-K”) As indicated in the Original Form 8-K, this Amendment is being filed to provide the determination of the per share purchase price and number of shares sold in connection with a sale of common stock on August 5, 2022.
Item 3.02. Unregistered Sales of Equity Securities.
On August 5, 2022, the Company sold 5,651.095 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for an aggregate offering price of $53,696.71, and a per share purchase price of $9.5020.
The sales of the above-referenced shares of Common Stock were made pursuant to subscription agreements entered into by the Company and its investors. Under the terms of the subscription agreements, investors are required to pay such amounts at the time of subscription.
The issuance of the above-referenced shares of Common Stock is exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and Regulation D thereunder.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Steele Creek Capital Corporation|
|By:||/s/ Douglas S. Applegate, Jr.|
|Name:||Douglas S. Applegate, Jr.|
|Title:||Chief Financial Officer|
|August 17, 2022|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fort Bliss to Implement Mission Critical Resiliency Upgrades
- Konica Minolta Wins Two Marketing Awards
- InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!